TMCnet News
Great Basin Expands Product Development LeadershipGreat Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, has appointed Suzette Chance, Ph.D. to serve as senior director of clinical affairs. In her role, Dr. Chance will lead clinical trial strategy and execution for Great Basin's diagnostic products, beginning with upcoming trials for: Candida Blood Infections Panel; SA Nasal Screen Test; CT/NG Test; Stool Bacterial Pathogens Panel; and Pertussis/Parapertussis Test. All five trials are slated to begin in 2016 with expected clearance timeframes throughout 2017. Dr. Chance has more than 20 years of experience in the in vitro diagnostics industry, and has a proven record of success taking product ideas from concept through commercialization, including clinical trials and U.S. Food & Drug Administration (FDA) clearance. Most recently, Dr. Chance served as senior director of research and development at Immucor GTI Diagnostics in Waukesha, Wis., where she specialized in transplantation and transfusion medicine. Prior to that, she served in R&D roles with Gen-Prob/Hologic and Genetic Testing Institute. Dr. Chance began her career as a scientist and biochemist with DuPont Medical Products in Glasgow, Del., where she created and established a new bio-analytical laboratory for the DuPont facility. She earned her B.S. degree in biochemistry at the University of Minnesota, her Ph.D. in biochemistry at Johns Hopkins University; School of Hygiene and Public Health, and completed a post-doctoral fellowship at Johns Hopkins University, School of Medicine, Department of Cell Biology and Anatomy. Dr. Chance has successfully shepherded more than 22 new products through the development and regulatory process in her career. "Great Basin is committed to a very aggressive schedule for delivering new tests and panels that meet the needs of our current customers and spur adoption of Great Basin's easy-to-use and cost-effective solution in new hospitals and labs," said Robert D. Jenison, chief technology officer, Great Basin Scientific. "Suzette's experience and leadership will be key to our ability to successfully deliver on our menu goals of nine cleared assays in 2017, and 16 to 17 assays in 2018. We are thrilled to welcome someone as knowledgeable and successful as Suzette to help us refine and expedite our clinical trial and FDA 510(K) submission processes as we embark on this exciting time of growth." About Great Basin Scientific Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com. Forward-Looking Statements This press release includes forward-looking statements regarding the Company's continuing business efforts related to its products, including but not limited to planned tests to be brought to clinical trial in 2016, target customer group and related statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160427005351/en/ |
